Ocular Therapeutix (OCUL) reported second-quarter 2026 net revenue of $13.5 million, flat with the prior-year quarter, and a net loss of $78.8 million, or $0.35 per share on both a basic and diluted basis. The company said cash and cash equivalents totaled $598.6 million as of June 30, 2026, with expected runway into 2028.
Ocular said its AXPAXLI wet AMD NDA submission remains on track for the fourth quarter of 2026 after a May 2026 FDA Type C meeting. A pre-NDA meeting is scheduled for the third quarter, and the company said the planned 505(b)(2) pathway could shorten review timing by up to 60 days.
- Total revenue, net was $13.5 million for Q2 2026, compared with $13.5 million in Q2 2025.
- Research and development expenses were $54.1 million, versus $51.1 million a year earlier.
- AXPAXLI post hoc SOL-1 analysis showed up to an estimated 72% reduction in treatment burden over 60 weeks versus projected on-label aflibercept dosing.
- SOL-R topline results are now expected in the first quarter of 2028 after planned trial amendments.
- Outstanding shares were approximately 225.0 million as of July 31, 2026.
$OCUL Insider Trading Activity
$OCUL insiders have traded $OCUL stock on the open market 17 times in the past 6 months. Of those trades, 1 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $OCUL stock by insiders over the last 6 months:
- PRAVIN DUGEL (See Remarks) has made 0 purchases and 3 sales selling 166,094 shares for an estimated $1,468,476.
- RICHARD L MD LINDSTROM purchased 60,229 shares for an estimated $461,354
- NADIA WAHEED (Chief Medical Officer) has made 0 purchases and 3 sales selling 26,201 shares for an estimated $220,876.
- DONALD NOTMAN (Chief Operating Officer) has made 0 purchases and 3 sales selling 22,936 shares for an estimated $204,869.
- SANJAY NAYAK (Chief Strategy Officer) has made 0 purchases and 3 sales selling 13,965 shares for an estimated $123,346.
- JEFFREY S. HEIER (Chief Scientific Officer) has made 0 purchases and 2 sales selling 6,075 shares for an estimated $50,059.
- PETER KAISER (Chief Development Officer) has made 0 purchases and 2 sales selling 5,777 shares for an estimated $47,596.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$OCUL Hedge Fund Activity
We have seen 147 institutional investors add shares of $OCUL stock to their portfolio, and 107 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DEEP TRACK CAPITAL, LP added 11,615,868 shares (+143.9%) to their portfolio in Q1 2026, for an estimated $98,386,401
- PRICE T ROWE ASSOCIATES INC /MD/ added 5,725,625 shares (+3338.1%) to their portfolio in Q1 2026, for an estimated $48,496,043
- POINT72 ASSET MANAGEMENT, L.P. added 4,518,737 shares (+444.6%) to their portfolio in Q1 2026, for an estimated $38,273,702
- TCG CROSSOVER MANAGEMENT, LLC removed 4,092,479 shares (-71.3%) from their portfolio in Q1 2026, for an estimated $34,663,297
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 4,004,350 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $33,916,844
- MILLENNIUM MANAGEMENT LLC removed 3,173,875 shares (-98.9%) from their portfolio in Q1 2026, for an estimated $26,882,721
- PARADIGM BIOCAPITAL ADVISORS LP removed 2,935,284 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $24,861,855
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
